In the coming weeks a license is set to be granted by the European Medicines Agency to allow clinicians to begin prescribing a potentially life changing treatment for Cystic Fibrosis suffers.
A combination of three different drugs – Elexacaftor, Tezacaftor and Ivacaftor, form the drug known as Trikafta (brand name). Prescriptions for Trikafta have been approved in the US since October 2019 for children over the age of 12. But the deal struck by NHS England could soon see patients with CF in the UK benefit from treatments that can have a significant positive effect. Early studies into Trikafta revealed an average improvement in lung function of between 10% and 13% – remarkable numbers in the CF community.
At Cystic Fibrosis Supporters we are over the moon with the latest news and thrilled it will help so many CF patients.